Claims for Patent: 7,741,060

Summary for Patent: 7,741,060

Title:	Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
Abstract:	The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.
Inventor(s):	Cantor; Thomas L. (El Cajon, CA), Gao; Ping (San Diego, CA)
Assignee:	Scantibodies Laboratory, Inc. (Santee, CA)
Application Number:	12/264,769
Patent Claims:	1. A method to verify the accuracy of a PTH assay using a parathyroid hormone assay control, wherein the parathyroid hormone (PTH) assay control comprises a composition having a known concentration of a whole PTH component mixed with a known concentration of a PTH fragment component, comprising: 1) a whole PTH component having an amino acid sequence set forth in SEQ ID NO:1 (PTH.sub.1-84), wherein the N-terminal amino acid residue of the PTH molecule must be intact; and 2) a PTH fragment component having an amino acid sequence set forth in SEQ ID NO:1 (PTH.sub.1-84), wherein the N-terminal amino acid residue of the PTH fragment starts at any position spanning position 2 through position 33 of the PTH.sub.1-84, the C-terminal amino acid residue of the PTH fragment ends at any position spanning position 35 through position 84 of the PTH.sub.1-84; and the PTH fragment has a minimal length of four amino acid residues; wherein the ratio of the whole PTH component to the PTH fragment component ranges between about 1% to about 99%, wherein said composition further comprises a protein matrix base, and wherein said assay control is lyophilized; wherein the method comprises one or more trials of the following: a) evaluating the PTH assay control utilizing a PTH assay having a specificity for a PTH fragment component in the PTH assay control; b) determining the concentration(s) of the PTH fragment components in the composition utilizing the assay of step a); and c) comparing the results obtained in step b) with the known concentration(s) of the one or more PTH fragment components in the PTH assay control or previously obtained values for the PTH assay control to verify the accuracy of the assay result for the PTH assay control; wherein the results of step c) are utilized to provide a basis for accepting, rejecting or interpreting PTH assay results obtained through the use of the PTH assay of step a) for non-control samples. 2. The method of claim 1, further comprising generating a standard deviation of the assay control results from previous assay trials after one or more trials in order to derive a basis for accepting or rejecting future assay runs. 3. The method of claim 1, wherein the PTH assay comprises two or more PTH assays, each having a specificity for a different PTH component, or a combination of the PTH components, present in the control. 4. The method of claim 1, wherein the PTH fragment component is PTH.sub.7-84. 5. The method of claim 1, wherein the PTH assay control is reconstituted to a concentration of whole PTH between 0.7 pmol/L and 3.9 pmol/L.

Details for Patent 7,741,060

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2023-09-29